[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640329":3},{"organization":4,"armGroups":7,"interventions":48,"overallOfficials":84,"centralContacts":88,"locations":96,"responsibleParty":112,"collaborators":10,"id":114,"slug":115,"hasResults":116,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":120,"eligibilityCriteria":121,"healthyVolunteers":116,"sex":122,"minAge":123,"maxAge":124,"enrollmentInfo":125,"targetDuration":10,"studyType":128,"phases":10,"briefSummary":129,"conditions":130,"keywords":136,"overallStatus":152,"whyStopped":10,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":162},{"fullName":5,"class":6},"Noom Inc.","INDUSTRY",[8,14,19,24,29,34,39,44],{"label":9,"type":10,"description":11,"interventionNames":12},"Education only (control)",null,"Arm 1 of FLOURISH: This is an active control condition in which participants will receive weekly informational newsletters for 12 months. This group will not have access to the Noom app (except for research purposes) and will not receive GLP-1 medications.",[13],"Behavioral: Education-only control",{"label":15,"type":10,"description":16,"interventionNames":17},"Noom Weight","Arm 2 of FLOURISH: Noom Weight users will have access to all in-app features. This group will not receive GLP-1 medications. Followed for 12 months.",[18],"Behavioral: Noom Weight",{"label":20,"type":10,"description":21,"interventionNames":22},"Standard GLP-1Rx","Arm 3 of FLOURISH: Standard GLP-1 users will follow a protocol for Noom's standard dose of compounded semaglutide and will have access to all in-app features. Followed for up to 12 months of program with 18 and 24 month follow-up post-GLP-1 discontinuation.",[23],"Drug: Semaglutide",{"label":25,"type":10,"description":26,"interventionNames":27},"Microdose GLP-1Rx","Arm 4 of FLOURISH: Microdose GLP-1 users will follow a microdose protocol of compounded semaglutide and will have access to all in-app features. Followed for up to 12 months of program with 18 and 24 month follow-up post-GLP-1 discontinuation.",[28],"Drug: Microdose semaglutide",{"label":30,"type":10,"description":31,"interventionNames":32},"Noom Plus","Arm 5 of FLOURISH: Participants will follow a protocol for Noom's standard dose of compounded tirzepatide and will have access to all in-app features. Followed for up to 12 months of program with 18 and 24 month follow-up post-GLP-1 discontinuation.",[33],"Drug: Tirzepatide",{"label":35,"type":10,"description":36,"interventionNames":37},"Noom Plus Microdose","Arm 6 of FLOURISH: Noom Plus Microdose users will follow a microdose protocol for compounded tirzepatide and will have access to all in-app features. Followed for up to 12 months of program with 18 and 24 month follow-up post-GLP-1 discontinuation.",[38],"Drug: Microdose tirzepatide",{"label":40,"type":10,"description":41,"interventionNames":42},"Noom Free Tier (control)","Arm 1 of THRIVE: This is an active control condition in which users enrolled in Noom's Free Tier program will have access to app features available to Free Tier. This group will not receive GLP-1 medications. Followed for 12 months.",[43],"Behavioral: Free Tier",{"label":45,"type":10,"description":46,"interventionNames":47},"Proactive Health","Arm 2 of THRIVE: Proactive health users will follow the microdose protocol for compounded semaglutide indicated for preventive health\u002Flongevity. They will have access to all in-app features. Followed for 12 months.",[28],[49,55,59,63,70,76,80],{"type":50,"name":15,"description":51,"armGroupLabels":52,"otherNames":53},"BEHAVIORAL","App-based behavioral weight management program providing structured educational content, coaching, and self-monitoring tools focused on nutrition, physical activity, and habit formation.",[15],[54],"Noom",{"type":50,"name":56,"description":57,"armGroupLabels":58,"otherNames":10},"Free Tier","Basic free-to-use tier of the Noom app with limited features; no structured behavioral program or medication.",[40],{"type":50,"name":60,"description":61,"armGroupLabels":62,"otherNames":10},"Education-only control","Weekly informational newsletters based on the CDC curriculum for 12 months; no structured behavioral program or medication.",[9],{"type":64,"name":65,"description":66,"armGroupLabels":67,"otherNames":68},"DRUG","Semaglutide","Standard clinical dosing of compounded semaglutide as part of Noom Med GLP-1Rx program per clinical standard of care, combined with behavioral coaching via the Noom app.",[20],[69],"Noom standard dose semaglutide",{"type":64,"name":71,"description":72,"armGroupLabels":73,"otherNames":74},"Tirzepatide","Standard clinical dosing of tirzepatide as part of Noom Plus program per clinical standard of care, combined with enhanced behavioral coaching.",[30],[75],"Noom standard dose tirzepatide",{"type":64,"name":77,"description":78,"armGroupLabels":79,"otherNames":10},"Microdose semaglutide","Below-standard clinical dosing (microdose) of compounded semaglutide as part of Noom Med GLP-1Rx Microdose program, combined with behavioral coaching via the Noom app.",[25,45],{"type":64,"name":81,"description":82,"armGroupLabels":83,"otherNames":10},"Microdose tirzepatide","Below-standard clinical dosing (microdose) of tirzepatide as part of Noom Plus Microdose program, combined with enhanced behavioral coaching.",[35],[85],{"name":86,"affiliation":5,"role":87},"Erin C Owen, PhD, MPH","PRINCIPAL_INVESTIGATOR",[89,93],{"name":86,"role":90,"phone":91,"phoneExt":10,"email":92},"CONTACT","(929)-644-7193","erin.owen@noom.com",{"name":94,"role":90,"phone":91,"phoneExt":10,"email":95},"Marielle Darwin, PhD","marielle.darwin@noom.com",[97],{"facility":98,"status":10,"city":99,"state":100,"zip":101,"country":102,"countryCode":103,"cosmosGeoPoint":104,"geoPoint":109,"contacts":110},"Noom, Inc.","Princeton","New Jersey","08542","United States","US",{"type":105,"coordinates":106},"Point",[107,108],-74.65905,40.34872,{"lat":108,"lon":107},[111],{"name":94,"role":90,"phone":91,"phoneExt":10,"email":95},{"type":113,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100640329","glp-1-medication--behavioral-health-programs-on-weight--metabolic-outcomes-flourish-and-thrive-prospective-cohort-study-100640329",false,"NCT07588984","GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study","GLP-1 Medication & Behavioral Health on Weight and Metabolic Outcomes: FLOURISH (Functional Longitudinal Outcomes Under Intentional Small Habits) & THRIVE (Trajectories of Health, Resilience & Integrated Vitality Evaluation) Cohort Study","FLOURISH","Inclusion Criteria:\n\n* Speaks English\n* Community-dwelling, community-living status\n* Able to ambulate independently, with or without aids or devices\n* Unless medically indicated, willingness to stay on current program for 12 months and participate in all study activities\n* Provides informed consent for study participation\n* Commitment and willingness to participate, as assessed by completion of decisional balance exercise\n* Program-specific eligibility:\n* Medication arms only: Meets standard of care program enrollment criteria for GLP-1 medication. Did not add other products or programs to Noom subscription.\n* Noom Weight only: Individual who is not interested in medication\n* Education-only Control Group: Individual who is interested in weight loss who is not currently enrolled in a structured weight loss program or medication program and does not intend to for the duration of the study Free Tier only: Willingness to use Free Tier\n\nExclusion Criteria:\n\n* Study screener completed more than 11 days after Noom program enrollment if participating in a Noom program (GLP-1 programs, Noom Weight, and Free Tier)\n* GLP-1 use in the last 24 weeks (prior to Noom program enrollment if in GLP-1 arm)\n* Female who is pregnant, breast-feeding, or intends to become pregnant during the 12-month program\n* Previous or planned (during the 12-month study) bariatric surgery\n* Active eating disorder\n* Active cancer\n* Type 1 diabetes or current Insulin use\n* Currently taking a medication known to cause weight gain (e.g., antipsychotics, antidepressants, diabetes medication, or corticosteroids)\n* Depression screen results in a PHQ-8 score of 20 or greater.\n\nAll medicated arms and Noom Weight arms (only):\n\n\\- Purchased more than the base Noom program offered for participant's specific arm\n\nGLP-1 Medication Arms Only:\n\n* GLP-1 agonist use is contraindicated (per program criteria) in members with:\n* Personal or family history of medullary thyroid cancer\n* Personal or family history of Multiple Endocrine Neoplasia Type 2 (MEN2)\n* Personal history of Pancreatitis","ALL","18 Years","64 Years",{"count":126,"type":127},2310,"ESTIMATED","OBSERVATIONAL","This research program includes two coordinated prospective studies (FLOURISH and THRIVE) evaluating the real-world effectiveness of Noom's digital health programs on weight, cardiometabolic biomarkers, physiological health indicators, and program engagement.\n\nFLOURISH is a 6-arm prospective cohort study comparing an Education-only control, Noom Weight, standard-dose compounded semaglutide, microdose compounded semaglutide, standard-dose tirzepatide (Noom Plus), and microdose tirzepatide (Noom Plus Microdose).\n\nTHRIVE is a nested 2-arm prospective study comparing a Proactive Health program to a Noom Free Tier control.\n\nParticipants complete monthly surveys, remote biomarker collection (Tasso device), connected-scale weigh-ins, and in-app biometric assessments (FaceScan, BodyScan). Microdose and Free Tier arms also use wearable fitness trackers. Primary outcomes are changes in cardiometabolic biomarkers, weight, body composition, and GLP-1 side effect profile. Total N = 2,310; 24-month duration.",[131,132,133,134,135],"Obesity & Overweight","Weight Loss","Preventative Health","Body Weight","Cardiovascular Disease Risk Factor",[137,138,139,140,141,142,143,144,145,146,147,148,149,150,151],"GLP-1","Microdose","weight","body composition","metabolic","biomarkers","longevity","glucagon-like peptide-1","semaglutide","tirzepatide","microdosing","digital health","weight loss","behavioral health","real world evidence","NOT_YET_RECRUITING","2026-05-08",{"date":155,"type":156},"2026-05-15","ACTUAL",{"date":158,"type":127},"2026-04-30",{"date":160,"type":127},"2029-05",{"name":5,"class":6},1]